Research in our lab is designed to better understand the process of drug resistance, in particular in hematological malignancies.
Our main research interests currently comprise the evaluation of molecular mechanisms contributing to the resistant leukemic clones with the focus on acute myeloid leukemia (AML). In particular, we aim to investigate following topics:
- drug resistance to FLT3 inhibitors
- ABC and SLC transporters, formation of the drug resistant subsets of AML cells, epigenetic regulation of their expression
- targeting drug resistance with novel drugs
- characterization of cell population initiating relapse in AML patients, more insights into the bone marrow microenvironment
- L-carnitine in healthy and malignant cells
- evaluation of expressional changes of ABC and SLC transporters in the proinflammatory environment. Involvement of L-carnitine and energetic metabolism in cellular development, differentiation and premalignant changes.
Currently, we collaborate with several national as well as foreign research teams, which allows us to evolve our scientific scope dynamically. We appreciate them and are opened for the establishment of the new ones. If you feel we could make meaningful work together, do not hesitate to contact us.